Core Insights - Defence Therapeutics Inc. has established its inaugural Scientific Advisory Board (SAB) to enhance its Accum®-Antibody drug conjugate (ADC) program, which has shown significant laboratory validation results [2][3][9] Group 1: Scientific Advisory Board Formation - The SAB consists of experts Rob Leanna, Danny Chui, and Brendan Hussey, who will provide scientific, technical, and strategic guidance for the company's programs [2][4] - The formation of the SAB aims to strengthen Defence's scientific foundation and support disciplined decision-making as the company advances its Accum® platform [9] Group 2: Accum®-Antibody Drug Conjugate Program - Defence's Accum®-ADC program has achieved laboratory validations, indicating a notable increase in intracellular accumulation and improved efficacy [3] - The SAB will help shape the direction and scientific priorities of the Accum®-enabled ADC programs as they progress towards clinical development [3][9] Group 3: Expertise of SAB Members - Rob Leanna brings extensive experience in ADC and drug-linker chemistry, having previously led development and regulatory strategy at AbbVie Inc. [5] - Danny Chui has over 20 years of experience in therapeutic antibody discovery and ADC development, contributing expertise in antibody engineering and preclinical pharmacology [6] - Brendan Hussey, with a background in biotechnology and investment banking, will align Defence's platform with market opportunities and partner expectations [7] Group 4: Company Overview - Defence Therapeutics is focused on engineering next-generation ADC products using its proprietary Accum® technology, which enhances the precision delivery of biologics [10] - The Accum® platform aims to improve efficacy and potency for biologics, thereby expanding patient access and market opportunities [10]

About LabGenius Therapeutics This collaboration combines LabGenius' AI/ML-driven antibody design capabilities with Sanofi's expertise in the development of therapeutic NANOBODY® molecules to co- optimise proteins for therapeutically valuable properties LabGenius Therapeutics is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company's discovery platform, EVAâ"¢, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, rob ...

Core Insights - Vivoryon Therapeutics N.V. reported advancements in its clinical program for varoglutamstat, particularly in improving kidney function in diabetic patients, and successfully completed a capital raise to support its strategic objectives [2][3][4] Financial Results - Revenues for the nine months ended September 30, 2025, were zero, consistent with the same period in 2024 [10] - Research and development expenses decreased by EUR 8.9 million to EUR 3.7 million compared to EUR 12.6 million in the same period of 2024, primarily due to reduced clinical development costs [11] - General and administrative expenses were EUR 4.0 million, down from EUR 4.9 million in the previous year, attributed to lower personnel costs [12] - The net loss for the nine months ended September 30, 2025, was EUR 7.6 million, compared to EUR 17.1 million for the same period in 2024 [12] - Cash and cash equivalents as of September 30, 2025, were EUR 2.5 million, down from EUR 9.4 million at the end of 2024 [13] Clinical Program Updates - The Phase 2 program for varoglutamstat demonstrated statistically significant and clinically meaningful improvements in kidney function (eGFR) compared to placebo in two independent studies [4] - A new analysis indicated a consistent treatment effect across patients with varying eGFR baseline levels, particularly in those with more impaired kidney function [3][7] - The company plans to initiate a dedicated Phase 2b clinical study in patients with diabetic kidney disease (DKD) stage 3b/4, pending additional funding or partnerships [4][16] Corporate Development - Vivoryon successfully completed a private placement raising EUR 5.1 million, extending its cash runway into Q3 2026 [6][14] - The company is actively exploring additional funding and partnership opportunities to support its DKD program and other development initiatives [16] - A new CFO, Marcus Irsfeld, will succeed Anne Doering, who is stepping down in December 2025 [15]

Core Insights - The company is evolving its strategy to a royalty-based model, which is a significant shift in its operational approach [2] Group 1: Strategic Evolution - The decision to move to a royalty-based model is driven by the need for financial advantages and better prioritization of the pipeline and portfolio [2] - The company aims to leverage this new model to enhance its financial stability and optimize its resource allocation [2]

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the lead plaintiff deadline for a class action lawsuit, which is January 16, 2026 [1] - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3] Case Details - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and prospects, particularly concerning the effectiveness of nimacimab [5] - Specific claims include that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages [5] Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any upfront costs through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, which involves directing the litigation on behalf of other class members [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting that many firms may lack the necessary experience and resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, failing to disclose critical information about the product's clinical benefits [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide a clinical advantage over BIMZELX [5].

Core Viewpoint - The Schall Law Firm is investigating Anavex Life Sciences Corp for potential violations of securities laws following a significant drop in share price after a negative trend vote on its Marketing Authorisation Application for blarcamesine [1] Group 1: Investigation Details - The investigation focuses on whether Anavex issued false or misleading statements or failed to disclose important information to investors [1] - Anavex announced on November 14, 2025, that it received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) regarding its Marketing Authorisation Application for blarcamesine [1] Group 2: Market Reaction - Following the announcement of the negative trend vote, shares of Anavex fell by more than 35.9% on the same day [1]

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.Connecticut-based fund Braidwell established a new position in ACADIA Pharmaceuticals (ACAD +1.77%), adding nearly 2.4 million shares, a stake valued at about $50.8 million as of September 30.What HappenedAccording to a filing with the U.S. Securities and Exchange Commission dated November 14, Braidwell disclosed a new stake in ACADIA Pharmaceuticals, acquiring nearly 2.4 million shares valued at approx ...

Soleno just turned profitable for the first time—right as a major fund made its move.Connecticut-based fund Braidwell initiated a new position in Soleno Therapeutics (SLNO +5.41%) during the third quarter, adding 1.3 million shares worth about $86.7 million, according to a November 14 SEC filing.What HappenedAccording to a Securities and Exchange Commission (SEC) filing dated November 14, Braidwell disclosed a new equity position in Soleno Therapeutics (SLNO +5.41%). The fund acquired nearly 1.3 million sha ...

Group 1: Capricor Therapeutics, Inc. - Capricor Therapeutics, Inc. leads the market with a remarkable 351.89% increase in its stock price, closing at $28.74, following advancements in its lead candidate, CAP-1002, for treating Duchenne muscular dystrophy [1][6] - The stock reached a new year-high of $40.37, with trading volume exceeding 48 million shares, attributed to a successful late-stage study for a heart condition associated with the disease [1][6] Group 2: Nauticus Robotics, Inc. - Nauticus Robotics, Inc.'s warrant (KITTW) saw a substantial rise of 150.92%, reaching $0.068, driven by technological breakthroughs in ocean robotics [2][6] - The company's stock (NASDAQ: KITT) experienced a 67.46% climb to $1.2101, with trading volume surging to over 72 million shares, reflecting investor interest in its innovative approach to oceanic exploration [2][6] Group 3: iRobot Corporation - iRobot Corporation experienced a significant uptick of 69.97% in its stock price, landing at $3.31, fueled by a strategic partnership aimed at expanding its product line into new markets [3][6] - The trading volume reached 166 million shares, indicating a strong market response compared to its usual trading activity [3] Group 4: Palladyne AI Corp. - Palladyne AI Corp.'s warrant (PDYNW) rounded out the top five with a 54.25% increase in its stock price to $0.10, reflecting advancements in AI and machine learning for robotic systems [4][6] - The increased trading activity underscores the dynamic nature of the market, where technological advancements can significantly impact company valuations [4][6] Group 5: Market Overview - The market's top gainers demonstrate the impact of technological advancements and strategic developments on company valuations, with Capricor Therapeutics, Nauticus Robotics, iRobot, and Palladyne AI Corp. all experiencing significant stock price increases [5][6] - These movements highlight the importance of innovation and strategic partnerships in driving investor interest and market performance [5]